RESUMO
BACKGROUND AND OBJECTIVES: To evaluate a regimen of induction and consolidation chemotherapy, followed by a post-remission therapy which depended on age and cytogenetics, in patients with primary acute myeloid leukemia. DESIGN AND METHODS: Two hundred patients up to 60 years old received idarubicin, standard dose cytarabine and etoposide as induction chemotherapy and one consolidation course including intermediate dose cytarabine and mitoxantrone. Subsequently, patients with favorable cytogenetics, [i.e., t(8;21), inv(16)] were scheduled to receive 2 courses of high-dose cytarabine. The remainder were scheduled for allogeneic stem cell transplantation (SCT), if Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
, Leucemia Mieloide Aguda/tratamento farmacológico
, Leucemia Mieloide Aguda/terapia
, Transplante de Células-Tronco
, Adolescente
, Adulto
, Citarabina/administração & dosagem
, Esquema de Medicação
, Etoposídeo/administração & dosagem
, Feminino
, Teste de Histocompatibilidade
, Humanos
, Leucemia Mieloide Aguda/classificação
, Leucemia Mieloide Aguda/imunologia
, Leucemia Mieloide Aguda/mortalidade
, Masculino
, Pessoa de Meia-Idade
, Probabilidade
, Estudos Prospectivos
, Análise de Sobrevida
, Condicionamento Pré-Transplante
RESUMO
We present the case of a man affected by an unclassified mature B-cell neoplasm with a bone marrow culture stimulated with TPA showing a 46,XY, t(11;13)(q13;q14)[14]/46,XY [6] karyotype. Fluorescent in situ hybridization demonstrated that the BCL1 oncogene is translocated (not rearranged) to chromosome band 13q14 and that a copy of D13S319 locus is deleted. To our knowledge, this is the first reported case with this novel cytogenetic aberration.